STOCK TITAN

Sensei Biotherapeutics, Inc. SEC Filings

SNSE NASDAQ

Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking clinical-stage biotech disclosures is never easy. Sensei Biotherapeutics’ pursuit of tumor-microenvironment activated antibodies produces dense risk factor pages, intricate R&D cost tables, and frequent funding 8-Ks. If you’ve ever opened the 10-K looking for VISTA trial data or sifted through Sensei Biotherapeutics insider trading Form 4 transactions, you know the challenge.

Stock Titan’s AI scans every Sensei Biotherapeutics quarterly earnings report 10-Q filing, delivers Sensei Biotherapeutics Form 4 insider transactions real-time, and offers Sensei Biotherapeutics SEC filings explained simply. Our platform highlights pipeline milestones, cash runway updates, and shelf-registration details in plain language. Whether you want a quick Sensei Biotherapeutics earnings report filing analysis or are understanding Sensei Biotherapeutics SEC documents with AI for deeper diligence, the answers surface in seconds.

Dive deeper without drowning in jargon. Compare option grants via Sensei Biotherapeutics executive stock transactions Form 4, skim a Sensei Biotherapeutics annual report 10-K simplified summary, or review the Sensei Biotherapeutics proxy statement executive compensation section to spot incentive shifts. Real-time alerts flag every Sensei Biotherapeutics 8-K material events explained, from trial pauses to capital raises. Investors use these insights to monitor insider sentiment before catalysts, track quarter-over-quarter R&D spend, and evaluate dilution risk—all without downloading massive PDFs. Our AI-powered summaries, expert context, and complete filing coverage turn regulatory complexity into actionable clarity.

Rhea-AI Summary

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE’s common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June – 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE’s ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company’s underlying fundamentals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Sensei Biotherapeutics (SNSE)?

The current stock price of Sensei Biotherapeutics (SNSE) is $8.02 as of July 17, 2025.

What is the market cap of Sensei Biotherapeutics (SNSE)?

The market cap of Sensei Biotherapeutics (SNSE) is approximately 11.5M.

What is the core focus of Sensei Biotherapeutics?

Sensei Biotherapeutics is focused on developing next-generation immuno-oncology therapeutics using conditionally active antibodies that target cancer within the tumor microenvironment.

How does the TMAb platform work?

The TMAb platform is engineered to activate selectively under the acidic conditions found in the tumor microenvironment, which helps to minimize off-target effects and enhance precise T-cell activation.

What makes Sensei's approach unique in the immuno-oncology field?

Sensei’s approach is unique because it employs conditionally active antibodies that leverage environmental cues in tumors to selectively disrupt immune suppression, thereby overcoming common challenges in cancer immunotherapy.

Which immune checkpoints are targeted by Sensei’s therapeutics?

The company targets checkpoints such as VISTA, a molecule known for its role in suppressing T-cell activity, particularly within the harsh conditions of the tumor microenvironment.

What development stage is Sensei Biotherapeutics in?

Sensei is a clinical stage company with several investigational products under clinical evaluation, demonstrating its commitment to advancing novel immuno-oncology treatments.

How does targeted activation in the tumor microenvironment benefit patients?

By activating the therapeutic antibodies only where the tumor conditions exist, Sensei’s technology aims to reduce systemic side effects and enhance the specificity and safety of cancer treatments.

How does Sensei differentiate itself from other companies?

Sensei differentiates itself through its proprietary, conditionally active antibody platform that specifically exploits the low pH environment of tumors, addressing both safety and efficacy challenges seen in traditional immunotherapies.

What types of cancers are targeted by Sensei’s therapeutic candidates?

Sensei’s clinical programs primarily target advanced solid tumors, including cancers that are traditionally resistant to standard immunotherapy, by focusing on the tumor microenvironment.
Sensei Biotherapeutics, Inc.

NASDAQ:SNSE

SNSE Rankings

SNSE Stock Data

11.53M
829.83k
34.22%
9.37%
0.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE